Press Archive
- Charles Francis: Weakening eye surgery laws places WV patients in jeopardy
- Mark D. Mayle, MD - 2022 Secretariat Award Recipients
- Dr. Larry Schwab recognized with 2020 International Blindness Prevention Award
- Wow Moment with Joseph A. LoCasio | Bio-Tissue | #WowWednesdays
- WVU Today | Moore, Oppe named recipients of Heebink award for Distinguished Service
- Cornea Transplant Restores Young Boy’s Sight After Fishing Accident
- Keep your eyes healthy and safe in the workplace
- Glaucoma Awareness Month
- Ophthalmologists Say 90 Percent of Work-Related Eye Injuries Can be Avoided by Wearing Eye Protection
- Five Tips to Avoid Toy-Related Eye Injuries
- Details
Intraocular lymphomas (i-OL) are rare and aggressive subsets of primary cerebral tumors. Little is known about the pathogenesis. This is explained by the scarcity of patients and the tiny amount of ocular fluid sampled for biological analyses. In most cases, i-OL is misdiagnosed because its clinical features can mimic other ocular conditions. To date, no independent biological tool is able to firmly diagnose i-OL; the combination of cytologic examination, immunochemistry, flow cytometry, and molecular analysis is required.
Read more: ISOLD: A New Highly Sensitive Interleukin Score for Intraocular Lymphoma Diagnosis
- Details
Intraocular pressure, the only modifiable risk factor for glaucoma, is traditionally lowered with topical medication, laser or invasive surgery.1,2 More recently, there has been increased interest in alternative methods for lowering intraocular pressure through the use of minimally invasive extraocular drug delivery implants, such as punctual plugs, as well as more invasive surgical implants or intraocular injectable medication depots. The main goal of these alternative methods of drug delivery is to supplant the need for daily topical medication instillation that is associated with side effects and poor adherence.
- Details
To review the role of anatomic endpoints in clinical trials for the study of nonexudative age-related macular degeneration (AMD) with an emphasis on a novel composite endpoint for the study of emerging therapies for intermediate AMD (iAMD).
Read more: Anatomic Clinical Trial Endpoints for Nonexudative Age-Related Macular Degeneration
- Details
To provide visual and anatomic outcomes for patients with retinal detachment (RD) in whom primary pneumatic retinopexy (PR) failed.
Read more: Outcomes after Failed Pneumatic Retinopexy for Retinal Detachment
- Details
To examine the impact of topical corticosteroid use after the start of antiamoebic therapy (AAT) on the outcomes of Acanthamoeba keratitis (AK) therapy.
- Details
Although primary congenital glaucoma (PCG) is a rare disease, it occurs worldwide. Surgery is the mainstay of treatment of PCG, with surgical success rates having improved dramatically over the past few decades to 70% to 80%.1 However, there are few reports of patient-reported outcomes in PCG.2,3 A diagnosis of a sight-threatening condition such as PCG in a newborn or very young child can have significant psychosocial implications for families, who may experience a range of emotions such as guilt, fear, sadness, anxiety, and grief.